Ergomed (LON:ERGO) said its co-development partner Aeterna Zentaris have received an important sign off for a potentially breakthrough drug for endometrial cancer.
It has been given what’s called a positive recommendation from US regulators that will allow it to push on with final trials.
The green light from the Data Safety Monitoring Board allows researchers to focus on concluding patient recruitment for the phase III clinical study, which is reported to be ahead of schedule.
Endometrial cancer, or cancer of the womb, is the most common gynecologic malignancy in developed countries and occurs when abnormal cells amass to form a tumor in the lining of the uterus. There will be 50,000 new cases in the US alone.
Aeterna and Ergomed will treat woman with zoptarelin doxorubicin, a hybrid molecule composed of a synthetic peptide carrier and the well-known chemotherapy agent, doxorubicin.
Read more: http://www.proactiveinvestors.co.uk/companies/news/79795/ergomed-and-partner-receive-safety-green-light-for-new-cancer-drug--79795.html